|
|
| | GP130-IN-1 Basic information |
| Product Name: | GP130-IN-1 | | Synonyms: | GP130-IN-1;Methanone, [5-hydroxy-2-(4-hydroxyphenyl)-1H-indol-1-yl](2,3,4,5,6-pentafluorophenyl)- | | CAS: | 2955243-69-1 | | MF: | C21H10F5NO3 | | MW: | 419.3 | | EINECS: | | | Product Categories: | | | Mol File: | 2955243-69-1.mol |  |
| | GP130-IN-1 Chemical Properties |
| Boiling point | 530.0±50.0 °C(predicted) | | density | 1.53±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 9.42±0.40(predicted) |
| | GP130-IN-1 Usage And Synthesis |
| Uses | GP130-IN-1 (compound 49) is a potent GP130 inhibitor with significant in vitro antitumor activity and higher selectivity than Bazedoxifene (HY-A0031). GP130-IN-1 induces ultrastructural changes in cells, causing cell cycle arrest in the G0/G1 phase in a time-dependent manner and triggering apoptosis and autophagy. GP130-IN-1 can be used in the study of triple-negative breast cancer[1]. | | References | [1] Wu P, et al. Structurally diverse design and synthesis of novel 2-phenylindole amide derivatives with anti-canine breast cancer activity[J]. Bioorganic Chemistry, 2024: 107788. DOI:10.1016/j.bioorg.2024.107788 |
| | GP130-IN-1 Preparation Products And Raw materials |
|